Patents by Inventor Simon Theodor Hansen

Simon Theodor Hansen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NON-COVALENT PROTEIN-HYALURONAN CONJUGATES FOR LONG-ACTING OCULAR DELIVERY
    Publication number: 20230279090
    Abstract: A conjugate may comprise a first component capable of binding to a therapeutic target in the eye, one or more second component(s) capable of binding to hyaluronan, and one or more third component(s) comprising hyaluronan, wherein each second component is covalently bound to the first component and non-covalently bound to a third component, a composition comprising the conjugate for use as a medicament or for use in the treatment of an eye disease and a method of treating an eye disease in a subject. Additionally, a therapeutic molecule targeted to a tissue in a patient may comprises a hyaluronic acid binding moiety and a therapeutically active agent, wherein the hyaluronic acid binding moiety comprises at least two link domains of Versican.
    Type: Application
    Filed: April 14, 2023
    Publication date: September 7, 2023
    Inventors: Stefan Dengl, Rami Hannoush, Simon Theodor Hansen, Peter Michael Huelsmann, Robert Franklin Kelley, Hubert Kettenberger, Shrenik Chetan Mehta, Devin Brent Tesar
  • HYALURONIC ACID BINDING DERIVATIVES OF VERSICAN (VG1) FOR LONG ACTING DELIVERY OF THERAPEUTICS
    Publication number: 20230256107
    Abstract: A conjugate may comprise a first component capable of binding to a therapeutic target in the eye, one or more second component(s) capable of binding to hyaluronan, and one or more third component(s) comprising hyaluronan, wherein each second component is covalently bound to the first component and non-covalently bound to a third component, a composition comprising the conjugate for use as a medicament or for use in the treatment of an eye disease and a method of treating an eye disease in a subject. Additionally, a therapeutic molecule targeted to a tissue in a patient may comprises a hyaluronic acid binding moiety and a therapeutically active agent, wherein the hyaluronic acid binding moiety comprises at least two link domains of Versican.
    Type: Application
    Filed: April 14, 2023
    Publication date: August 17, 2023
    Inventors: Robert Franklin Kelley, JR., Shrenik Chetan Mehta, Devin Brent Tesar, Rami Hannoush, Simon Theodor Hansen, Stefan Dengl, Hubert Kettenberger, Peter Michael Huelsmann